Armentano *86, Bibbins-Domingo '87 and Garrick '90 named to MOL Advisory Council

Department Announcement
Posted on July 16, 2020

Three new members were appointed to the Department of Molecular Biology Advisory Council. The Council meets periodically to review the programmatic aspects of the Department as well as provides strategic direction. The Council consists of about 20 distinguished scientists and biotech executives, many of whom are alumni.

 

Donna Armentano
Dr. Donna Armentano *86

Donna Armentano is Executive Director and Global Head of Gene Therapy in Pfizer’s Emerging Science and Innovation team.  She is responsible for external partnerships and collaborations in nucleic acid delivery to develop Pfizer’s pipeline in treatment of Rare Diseases.  Prior to her role at Pfizer, Donna was head of a research team at Genzyme/Sanofi for 24 years that focused on developing gene therapies for a broad array of therapeutic indications including CF, Hemophilia A and B, Lysosomal Storage Diseases, Diabetes, Peripheral Artery disease and OA.  She has experience in multiple viral vector platforms (retrovirus, lentivirus, adenovirus and AAV) and strategies to improve vector production.  Donna received a Bachelor of Arts degree from Cornell University in Biochemistry and doctorate degree from Princeton University in Molecular Biology where she studied retroviral vectors for adenosine deaminase deficiency.  She did her post-doctoral research at Baylor College of Medicine which focused on developing gene therapies for hemophilia and PKU.  Donna has numerous publications and issued patents in the field of Gene Therapy.

 

Kirsten Bibbins-Domingo
Dr. Kirsten Bibbins-Domingo '87

Kirsten Bibbins-Domingo, PhD, MD, MAS is the Professor and Chair of the Department of Epidemiology and Biostatistics, and the Lee Goldman, MD Endowed Chair and Professor of Medicine at the University of California, San Francisco.   She is the inaugural Vice Dean for Population Health and Health Equity in the UCSF School of Medicine.  She co-founded the UCSF Center for Vulnerable Populations at Zuckerberg San Francisco General Hospital that focuses on actionable research to increase health equity and reduce health disparities in at risk communities.  She is one of the Principal Investigators for the UCSF Clinical and Translational Sciences Institute, and she leads the newly launched UCSF COVID Community Public Health Initiative.

Dr. Bibbins-Domingo is a general internist and cardiovascular epidemiologist whose scholarship includes observational epidemiology, pragmatic trials, and simulation modeling to examine clinical and public health approaches to prevention in the US and globally.  She previously served on and led the US Preventive Services Task Force from 2010-2017. She is an inducted member of the American Society for Clinical Investigation, the Association of American Physicians, and the National Academy of Medicine.

Dr. Bibbins-Domingo graduated from Princeton in 1987 with a degree in molecular biology and the Princeton School of Public and International Affairs.  She is currently a trustee of Princeton University.

 

Owen Garrick
Dr. Owen Garrick '90

Owen Garrick, MD MBA is President &CEO of Bridge Clinical Research (BCR). BCR is a global clinical research and health communications firm focused on drug development, scientific advancement and patient engagement. At BCR, Dr. Garrick, leadsthe Clinical Trials, Research Analytics, Health Services Research and Healthcare Communications business units. He serves as an advisor to the Stanford Precision Health for Ethnic and Racial Equity Center (SPHERE) which is one of five NIH centers focused on precision-medicine tools to improve the health of underserved ethnic and racial groups. Dr. Garrick is a Stanford co-investigator for research using genetic testing kits exploring the reasons why minority patients may or may not participate in genetic testing and is a Stanford sub-awardee for a project specifically focused on the willingness of patients with sickle cell disease to participate in precision medicine research. Concurrently, he is working on studies involving Nephrology and Multiple Sclerosis.

Dr. Garrick is a nationally recognized leader in the field of research and research ethics. He is a member of the National Genome Research Institute’s (NHGRI) Genomic Education of Healthcare Professionals Partnership. He was appointed to a term as a member of the Department of Health and Human Services Secretary’s Advisory Council on Human Research Protections (SACHRP) from 2012-2016 where he co-authored industry advisory documents around biospecimen data security and patient engagement in research. Dr. Garrick currently serves on the Executive Committee of Professional Responsibility in Medicine & Research (PRIMR) and was formerly a member of Quorum Review’s IRB.Dr. Garrick earned his MD from Yale School of Medicine and his MBA from Wharton School of Business. He holds an AB in Psychology from Princeton University.